NCT05257902Completed
Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints
Evaluation of Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints: a Double-blinded, Placebo-controlled, Randomization, Multicenter Investigator-initiated Trial
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
To evaluate the efficacy of choline alphoscerate on improving symptoms related to depression, anxiety, and subjective memory complaints compared to placebo in patients with Major Depressive Disorder(MDD) accompanied with subjective cognitive decline, who are over the age of 60.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 120 (actual)
- First submitted
- 17 Jan 2022
- Start date
- 19 Aug 2022
- Primary completion date
- 27 May 2026
- Lead sponsor
- Samsung Medical Center
- Diseases
- Depression
- NCT number
- NCT05257902
What you commit to
- Study type: Interventional
- Participants enrolled: 120
- From 19 Aug 2022 to the primary completion date, 27 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who have been taking medication of typical antipsychotics, mood stabilizer, cognitive enhancer including donepezil, rivastigamine, galantamine, and memantine within 1months.
- Participants who had previous history of liver disease or renal disease
Other illness
- Diagnosed as schizophrenia, bipolar disorder, PTSD, OCD or other significant mental disorder under the criteria of DSM-5 (only the participants who had depressive disorder, sleep disorder, and the anxiety disorder are allowed to be included)
- Who have medically unstable disease (only the participants, who have diabetes mellitus or hypertension under control with stable medication for 3 months could be included)
- Diagnosed as dementia or mild cognitive impairment
- Participants who had allergic reaction to choline alfoscerate
- Other specific condition, which could be inappropriate for the trial inclusion, under the judgement of the principal investigator
Other
- Participants who are already taking choline alfoscerate within 4 weeks of period
Who the study is looking for
- Age ≥ 60 years
- Diagnosed as MDD under the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and confirmed with MINI-Depression
- HAM-D ≥ 14
- MMSE ≥ 20
- Who had continuous subjective memory complaints more than 6 months before the period of screening
- Who had taking antidepressants longer than 1 month in the period of screening
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.